Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04147260 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT04147260 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 85 participants.
The verdict
NCT04147260, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
To evaluate the photosensitivity potential of BI 730357
Interventions
- DRUG Ciprofloxacin
- DRUG BI 730357
- DRUG Placebo to match BI 730357
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2020-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04147260
The ClinicalTrials.gov registry entry for NCT04147260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ciprofloxacin is the first listed.
NCT04147260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04147260 about?
NCT04147260 is a clinical study titled "Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin". To evaluate the photosensitivity potential of BI 730357
What is the current status of trial NCT04147260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2019-11-06. Estimated completion is 2020-09-09.
What interventions are being tested in trial NCT04147260?
The interventions under investigation include: Ciprofloxacin (DRUG), BI 730357 (DRUG), Placebo to match BI 730357 (DRUG).
Who is sponsoring clinical trial NCT04147260?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.